Shahram Tahmasebian

Shahram Tahmasebian

Auto-generated profile, based on publicly available information

Shahram Tahmasebian

Cellular and Molecular Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015 in Acta Informatica Medica
Verified
Journal Article
Open access
PDF file
MRMehdi Rasoolimoghadam
Mehdi Rasoolimoghadam
RSReza Safdari
Reza Safdari
MGMarjan Ghazisaeidi
Marjan Ghazisaeidi
MMMohammadReza Maharanitehrani
MohammadReza Maharanitehrani
STShahram Tahmasebiyan
Shahram Tahmasebiyan
Type II Diabetes is the most common diseases of metabolic disorders and the treatment of oral anti-diabetic drug use takes place But The problem of using multi-drug and interactions at the same time is an issue that has always been a major challenge And diagnosis of drug interactions, particularly in Diabetic patients due to the problem with the disease is very important. The purpose of this studying is, to design a clinical assistant decided to use this approach to determine the type II diabetes drug interactions this makes it easy for those who are active in the field. Study is Developmental that to determine the content of the system a self-made checklist was used. Checklist Validity and reliability has been confirmed by four professors. The Research community to determine the content of the system was country endocrine that are 124 people. The sample size was calculated using Cochran that was 57 people. The Score of checklist was calculated in SPSS version 20 .finally, the checklist was approved by at least 70% points. The system by using Microsoft SQL server 2008 and visual Studio 2012 development environment was designed in C#.net. In the end, In order to evaluate the software to determine the level of satisfaction, usability and ease of use, designed systems sharing with all Medical Informatics students of Tehran University of Medical Sciences. For this purpose a self-made questionnaire was used. Questionnaire Validity has been confirmed by four professors and reliability was assessed by Cronbach method. The results of the survey are showing that the majority of students found out and believed the software is useful and easy to use and generally expressed their satisfaction software. The methodology provides a suitable approach for analysis and modeling of data in the medical field and the performance is good.

1 January 2016 in Acta Informatica Medica
Verified
Journal Article
Open access
PDF file
STShahram Tahmasebian
Shahram Tahmasebian
MLMostafa Langarizadeh
Mostafa Langarizadeh
MGMarjan Ghazisaeidi
Marjan Ghazisaeidi
MMMahdavi Mazdeh
Mahdavi Mazdeh
Case-based reasoning (CBR) systems are one of the effective methods to find the nearest solution to the current problems. These systems are used in various spheres as well as industry, business, and economy. The medical field is not an exception in this regard, and these systems are nowadays used in the various aspects of diagnosis and treatment. In this study, the effective parameters were first extracted from the structured discharge summary prepared for patients with chronic kidney diseases based on data mining method. Then, through holding a meeting with experts in nephrology and using data mining methods, the weights of the parameters were extracted. Finally, fuzzy system has been employed in order to compare the similarities of current case and previous cases, and the system was implemented on the Android platform. The data on electronic discharge records of patients with chronic kidney diseases were entered into the system. The measure of similarity was assessed using the algorithm provided in the system, and then compared with other known methods in CBR systems. Developing Clinical fuzzy CBR system used in Knowledge management framework for registering specific therapeutic methods, Knowledge sharing environment for experts in a specific domain and Powerful tools at the point of care.

4 July 2023 in BMC Bioinformatics
Verified
Journal Article
Open access
PDF file
RMRoohallah Mahdi-Esferizi
Roohallah Mahdi-Esferizi
BHBehnaz Haji Molla Hoseyni
Behnaz Haji Molla Hoseyni
AMAmir Mehrpanah
Amir Mehrpanah
YGYazdan Golzade
Yazdan Golzade
ANAli Najafi
Ali Najafi
STShahram Tahmasebian
Shahram Tahmasebian
Background: P4 medicine (predict, prevent, personalize, and participate) is a new approach to diagnosing and predicting diseases on a patient-by-patient basis. For the prevention and treatment of diseases, prediction plays a fundamental role. One of the intelligent strategies is the design of deep learning models that can predict the state of the disease using gene expression data. Results: We create an autoencoder deep learning model called DeeP4med, including a Classifier and a Transferor that predicts cancer's gene expression (mRNA) matrix from its matched normal sample and vice versa. The range of the F1 score of the model, depending on tissue type in the Classifier, is from 0.935 to 0.999 and in Transferor from 0.944 to 0.999. The accuracy of DeeP4med for tissue and disease classification was 0.986 and 0.992, respectively, which performed better compared to seven classic machine learning models (Support Vector Classifier, Logistic Regression, Linear Discriminant Analysis, Naive Bayes, Decision Tree, Random Forest, K Nearest Neighbors). Conclusions: Based on the idea of DeeP4med, by having the gene expression matrix of a normal tissue, we can predict its tumor gene expression matrix and, in this way, find effective genes in transforming a normal tissue into a tumor tissue. Results of Differentially Expressed Genes (DEGs) and enrichment analysis on the predicted matrices for 13 types of cancer showed a good correlation with the literature and biological databases. This led that by using the gene expression matrix, to train the model with features of each person in a normal and cancer state, this model could predict diagnosis based on gene expression data from healthy tissue and be used to identify possible therapeutic interventions for those patients.

25 March 2024 in BMC Cancer
Verified
Journal Article
Open access
PDF file
RMRoohallah Mahdi-Esferizi
Roohallah Mahdi-Esferizi
ZSZahra Shiasi
Zahra Shiasi
RHRazieh Heidari
Razieh Heidari
ANAli Najafi
Ali Najafi
IMIssa Mahmoudi
Issa Mahmoudi
STShahram Tahmasebian
Shahram Tahmasebian
Background: The need for intelligent and effective treatment of diseases and the increase in drug design costs have raised drug repurposing as one of the effective strategies in biomedicine. There are various computational methods for drug repurposing, one of which is using transcription signatures, especially single-cell RNA sequencing (scRNA-seq) data, which show us a clear and comprehensive view of the inside of the cell to compare the state of disease and health. Methods: In this study, we used 91,103 scRNA-seq samples from 29 patients with colorectal cancer (GSE144735 and GSE132465). First, differential gene expression (DGE) analysis was done using the ASAP website. Then we reached a list of drugs that can reverse the gene signature pattern from cancer to normal using the iLINCS website. Further, by searching various databases and articles, we found 12 drugs that have FDA approval, and so far, no one has reported them as a drug in the treatment of any cancer. Then, to evaluate the cytotoxicity and performance of these drugs, the MTT assay and real-time PCR were performed on two colorectal cancer cell lines (HT29 and HCT116). Results: According to our approach, 12 drugs were suggested for the treatment of colorectal cancer. Four drugs were selected for biological evaluation. The results of the cytotoxicity analysis of these drugs are as follows: tezacaftor (IC10 = 19 µM for HCT-116 and IC10 = 2 µM for HT-29), fenticonazole (IC10 = 17 µM for HCT-116 and IC10 = 7 µM for HT-29), bempedoic acid (IC10 = 78 µM for HCT-116 and IC10 = 65 µM for HT-29), and famciclovir (IC10 = 422 µM for HCT-116 and IC10 = 959 µM for HT-29). Conclusions: Cost, time, and effectiveness are the main challenges in finding new drugs for diseases. Computational approaches such as transcriptional signature-based drug repurposing methods open new horizons to solve these challenges. In this study, tezacaftor, fenticonazole, and bempedoic acid can be introduced as promising drug candidates for the treatment of colorectal cancer. These drugs were evaluated in silico and in vitro, but it is necessary to evaluate them in vivo.

1 January 2024 in International Journal of Telemedicine and Applications
Verified
Journal Article
Open access
ZPZahra Parsaei
Zahra Parsaei
MJMajid Jangi
Majid Jangi
STShahram Tahmasebian
Shahram Tahmasebian
AEAsghar Ehteshami
Asghar Ehteshami
Introduction: The Virtual Clinic Mobile Application (VCMA) is a valuable tool for managing and remotely monitoring patients with various medical conditions. It can alleviate the strain on outpatient services and offer follow‐up options for patients who do not require a physical examination. A thorough understanding of recent literature can assist in identifying suitable functionalities for new development and future improvement of current applications (apps). This review study is aimed at identifying functional and nonfunctional requirements for VCMA.Methods: This study conducted a systematic search using databases such as PubMed, Scopus, ISI Web of Science, Science Direct, ProQuest, and IEEE to gather requirements of VCMA articles published in English from the inception of the databases up to April 2022. Out of a total of 1223 articles, 76 met the inclusion criteria. These articles were then analyzed using conventional content analysis to extract and categorize their requirements.Results: Two main themes and 8 subthemes in terms of VCMA requirements were extracted as follows: (1) functional requirements with 3 subthemes (demographic data documentation, health record, general features of the user interface (UI)); (2) nonfunctional requirements with 5 subthemes (usability, accessibility, compatibility, efficiency, and security).Conclusion: The findings highlight the importance of mHealth solutions for virtual care and the need for the development of apps based on the extracted functional and nonfunctional requirements for VCMA; however, controlled trials are necessary. It is recommended that transparent reporting of mHealth interventions be prioritized to enable effective interpretation of the extracted data.

1 April 2017 in Indian Journal of Science and Technology
Verified
Journal Article
Open access
PDF file
HEHamideh Ehtesham
Hamideh Ehtesham
RSReza Safdari
Reza Safdari
STShahram Tahmasebian
Shahram Tahmasebian
Background: Collecting and analyzing large volumes of disparate datasets are of major challenges arisen from the emergence of Big Data in the field of health. But the technology of Big Data is also associated with promising opportunities which can provide improvement of performance and facilitation of innovation in organizations. Objective: Since determining the lifetime is a practical approach regarding recognition of a phenomenon and its management, this paper aimed at identifying the challenges and opportunities of managing Big Data in the area of health at different stages of the lifecycle of Big Data. Methodology: This article is a structured review. After an initial review, 6 phases was detected in the lifecycle of Big Data, then the processes of traditional data were briefly reviewed in each phase, and the challenges associated with the emergence of Big Data and the solutions for their optimal management were discussed. Results: This study offers a broad over view of the advent of Big Data in the health sector, and provides a clear and accurate picture of the processes before and after its emergence through a comparative-based survey in each phase. The article points out innovations and modern methods of collection, pre-processing, and analysis of Big Data as well as the process of data extracting. It also describes cloud computing applications in the storage and release of Big Data. Conclusions: Our findings indicate that management of Big Data in health, based on its lifecycle, is resourceful for managers and policy-makers, in order to benefit from the technological features of Big Data with a managerial approach, to evaluate challenges, to apply innovative solutions at each phase of Big Data maturation, and to advance towards a new level of innovation, competitiveness, and productivity.